Astrana Health director granted 4,991 restricted shares

Kitayama Mitchell W reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kitayama Mitchell W reported acquisition or exercise transactions in this Form 4 filing.

Astrana Health, Inc. director Mitchell W. Kitayama received a grant of 4,991 shares of restricted common stock as equity compensation. The award was granted at no cash cost per share under the company’s 2024 Equity Incentive Plan and will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Kitayama directly holds a total of 32,837 shares of Astrana Health common stock, including the unvested restricted shares.

Insider Trade Summary

Grant/Award: 4,991 shares

Grant/Award 1 txn

Insider Kitayama Mitchell W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,991	$0.00	$0.00

Holdings After Transaction: Common Stock — 32,837 shares (Direct)

Footnotes (2)

1. F1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
2. F2. Includes 4,991 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Restricted stock grant: 4,991 shares Grant price per share: $0.00 per share Holdings after transaction: 32,837 shares +2 more

5 metrics

Restricted stock grant 4,991 shares Equity award to director Mitchell W. Kitayama

Grant price per share $0.00 per share Reported grant price for restricted common stock

Holdings after transaction 32,837 shares Total common stock directly held after grant

Vesting date Earlier of June 10, 2027 or 2027 annual meeting Restricted stock vesting condition

Transaction code A (Grant, award, or other acquisition) Indicates equity award, not open-market trade

Key Terms

restricted stock, 2024 Equity Incentive Plan, vest, annual meeting of stockholders

4 terms

restricted stock financial

"Includes 4,991 shares of restricted stock, which will vest on the earlier of June 10, 2027..."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2024 Equity Incentive Plan financial

"Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan..."

vest financial

"which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Astrana Health (ASTH) report for Mitchell W. Kitayama?

Astrana Health reported that director Mitchell W. Kitayama received 4,991 shares of restricted common stock as an equity award. The shares were granted at no cash cost under the 2024 Equity Incentive Plan, increasing his direct holdings to 32,837 shares of common stock.

When do Mitchell W. Kitayama’s new Astrana Health (ASTH) restricted shares vest?

The 4,991 restricted shares granted to Mitchell W. Kitayama vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual meeting of stockholders. Until vesting, they remain subject to the plan’s restrictions but count toward his reported holdings.

How many Astrana Health (ASTH) shares does Mitchell W. Kitayama hold after this Form 4?

After the reported grant, Mitchell W. Kitayama directly holds 32,837 shares of Astrana Health common stock. This figure includes the 4,991 newly granted restricted shares, which will vest based on the time- or meeting-based schedule described in the equity award footnotes.

Was Mitchell W. Kitayama’s Astrana Health (ASTH) award an open-market stock purchase?

No, the 4,991 shares were granted as restricted stock under Astrana Health’s 2024 Equity Incentive Plan at a reported price of $0.00 per share. This reflects a compensation-related equity award, not an open-market purchase or sale on a public securities exchange.

What plan governs the new restricted stock granted at Astrana Health (ASTH)?

The 4,991 restricted shares were granted under Astrana Health’s 2024 Equity Incentive Plan. The footnotes explain that these shares vest on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting, aligning the award with director service over that period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kitayama Mitchell W

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVE, 2ND FLOOR

(Street)

ALHAMBRA CALIFORNIA 91801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		4,991(1)	A	$0	32,837(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

2. Includes 4,991 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ Kathy Diep, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)